Klin Onkol 2003; 16(Suppl 2003): 125-126.
Abstract: Immunotherapy, which is one of the basic therapeutic modalities, belongs to the oldiest anticancer therapeutic procedures. First attempts for cure of malignant tumors with antibodies and immunity stimulation were done in ninteenth century. Now are running clinical trials with cytokines, monoclonal antibodies, dendritic cells and gene immunotherapy. We finished study based on interleukin-2 with interferon a administration after high-dosed chemotherapy followed by autologous hematopoietic progenitor cells transplantation. This study demonstrated good tolerence but there was not significant improvemt of survival. We have limited experience with combination of interleukinu-2, interferon and cytostatic drugs in renall-cell carcinoma, which is rare in childhood, and with rituximab (therapeutic monoclonal antibody against antigen CD20) in slected cases of recurrent B non-Hodgkin lymphomas. Randomised study based on administration of anti GD2 monoclonal antibody in high-risk neuroblastoma is under preparation and Czech republic will take part in this study.
